


ABSTRACTINDOLAMID DERIVATIVES WHICH POSSESS
GLYCOGENPHOSPHORYLASE INHIBITORY ACTIVITY

Heterocyclic amides of formula (1)



wherein:

is a single or double bond;

A is phenylene or heteroarylene;

m is 0, 1 or 2;

n is 0, 1 or 2;

R¹ is selected from for example halo, nitro, cyano, hydroxy, carboxy;

r is 1 or 2;

Y is -NR²R³ or -OR³;

R² and R³ are selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C₁₋₄alkyl (optionally substituted by 1 or 2 R⁸ groups);

R⁴ is selected from for example hydrogen, halo, nitro, cyano, hydroxy, C₁₋₄alkyl, and C₁₋₄alkanoyl;

R⁸ is selected from for example hydroxy, -COCOOR⁹, -C(O)N(R⁹)(R¹⁰), -NHC(O)R⁹, (R⁹)(R¹⁰)N- and -COOR⁹;

R⁹ and R¹⁰ are selected from for example hydrogen, hydroxy, C₁₋₄alkyl (optionally substituted by 1 or 2 R¹³);

R¹³ is selected from hydroxy, halo, trihalomethyl and C₁₋₄alkoxy;

or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.